ORG 10172: a Low Molecular Weight Heparinoid Anticoagulant with a Long Half-life in Man

Overview

Journal Br J Clin Pharmacol

Specialty Pharmacology

Date 1987 Jun 1

PMID 3606928

Citations 14

Authors

I D Bradbrook

H N Magnani

H C Moelker

P J Morrison

J Robinson

H J Rogers

R G Spector

T Van Dinther

H Wijnand

Affiliations

Soon will be listed here.

Abstract

ORG 10172 is a heparinoid with mean molecular weight 6500 daltons. Intravenous bolus injections of ORG 10172 were compared with placebo and heparin injections in 91 separate studies in 83 healthy male subjects. 6400 units ORG 10172 produced a mean maximum change of 14.7 s in kaolin cephalin time (c.f. greater than 120 s for 5000 units heparin). Changes in prothrombin time were minimal (1.6 s for 6400 units ORG 10172 and 4.5 s after 5000 units heparin). A dose-related increase in bleeding time occurred after ORG 10172 and at high doses (greater than 3200 units) some secondary bleeding, which was never serious, occurred at between 1 and 4 h after incision. A dose-dependent reduction in ex vivo platelet adhesiveness was found at 10 min after ORG 10172 injection. ORG 10172 promoted a much smaller release of lipoprotein lipase as compared with heparin. The effect of ORG 10172 on plasma factor Xa activity (one measure of its action) was described by a biexponential decay with a mean distribution half-life of 2.34 (s.e. mean 0.16) h and mean disposition half-life of 17.6 (s.e. mean 1.1) h. It thus has a much longer duration of effect than heparin. There was a linear relationship of plasma anti-Xa response to increasing dose although there was some variability only partly explained by differences in body weight or surface area. ORG 10172 administration by bolus intravenous injection was well tolerated and there was no evidence of adverse effects on clinical chemistry or haematology tests.

Citing Articles

Danaparoid-Consensus Recommendations on Its Clinical Use.

Bauersachs R, Lindhoff-Last E, Klamroth R, Koster A, Schindewolf M, Magnani H Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770426 PMC: 11677338. DOI: 10.3390/ph17121584.

Recombinant human soluble thrombomodulin and danaparoid combination anticoagulant therapy for disseminated intravascular coagulation in a child with streptococcal toxic shock syndrome: A case report.

Kato Y, Kawaguchi H, Iwataki S, Kihara H, Okada S Exp Ther Med. 2022; 24(6):714.

PMID: 36382099 PMC: 9634338. DOI: 10.3892/etm.2022.11650.

The design and synthesis of new synthetic low-molecular-weight heparins.

Chandarajoti K, Liu J, Pawlinski R J Thromb Haemost. 2016; 14(6):1135-45.

PMID: 26990516 PMC: 4907857. DOI: 10.1111/jth.13312.

Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Garcia D, Baglin T, Weitz J, Samama M Chest. 2012; 141(2 Suppl):e24S-e43S.

PMID: 22315264 PMC: 3278070. DOI: 10.1378/chest.11-2291.

Use of tranexamic acid for disseminated intravascular coagulation with excessive fibrinolysis associated with aortic dissection in a patient with chronic renal failure.

Kimura S, Odawara J, Aoki T, Yamakura M, Takeuchi M, Watanabe Y Int J Hematol. 2009; 89(4):549-552.

PMID: 19381761 DOI: 10.1007/s12185-009-0309-2.

References

JAQUES L . Heparins--anionic polyelectrolyte drugs. Pharmacol Rev. 1979; 31(2):99-166. View

Holmer E, Lindahl U, Backstrom G, Thunberg L, Sandberg H, SODERSTROM G . Anticoagulant activities and effects on platelets of a heparin fragment with high affinity for antithrombin. Thromb Res. 1980; 18(6):861-9. DOI: 10.1016/0049-3848(80)90208-x. View

Wilson 3rd J, Bynum L, Parkey R . Heparin therapy in venous thromboembolism. Am J Med. 1981; 70(4):808-16. DOI: 10.1016/0002-9343(81)90537-4. View

Young V, Giles A, Pater J, Corbett W . Sex differences in bleeding time and blood loss in normal subjects following aspirin ingestion. Thromb Res. 1980; 20(5-6):705-9. DOI: 10.1016/0049-3848(80)90160-7. View

Carter C, Kelton J, Hirsh J, Gent M . Relationship between the antithrombotic and anticoagulant effects of low molecular weight heparin. Thromb Res. 1981; 21(1-2):169-74. DOI: 10.1016/0049-3848(84)90045-8. View

Meuleman D, Hobbelen P, van Dedem G, Moelker H . A novel anti-thrombotic heparinoid (Org 10172) devoid of bleeding inducing capacity: a survey of its pharmacological properties in experimental animal models. Thromb Res. 1982; 27(3):353-63. DOI: 10.1016/0049-3848(82)90082-2. View

Ockelford P, Carter C, Mitchell L, Hirsh J . Discordance between the anti-Xa activity and the antithrombotic activity in an ultra-low molecular weight heparin fraction. Thromb Res. 1982; 28(3):401-9. DOI: 10.1016/0049-3848(82)90121-9. View

Ofosu F, Modi G, Cerskus A, Hirsh J, Blajchman M . Heparin with low affinity to antithrombin III inhibits the activation of prothrombin in normal plasma. Thromb Res. 1982; 28(4):487-97. DOI: 10.1016/0049-3848(82)90165-7. View

Henny C, ten Cate H, Ten Cate J, Surachno S, van Bronswijk H, Wilmink J . Use of a new heparinoid as anticoagulant during acute haemodialysis of patients with bleeding complications. Lancet. 1983; 1(8330):890-3. DOI: 10.1016/s0140-6736(83)91326-0. View

10.

Mikhailidis D, Barradas M, Mikhailidis A, Magnani H, Dandona P . Comparison of the effect of a conventional heparin and a low molecular weight heparinoid on platelet function. Br J Clin Pharmacol. 1984; 17(1):43-8. PMC: 1463302. DOI: 10.1111/j.1365-2125.1984.tb04997.x. View

11.

ten Cate H, Henny C, Buller H, Ten Cate J, Magnani H . Use of a heparinoid in patients with hemorrhagic stroke and thromboembolic disease. Ann Neurol. 1984; 15(3):268-70. DOI: 10.1002/ana.410150311. View

12.

Decousus H, Croze M, Levi F, Jaubert J, Perpoint B, De Bonadona J . Circadian changes in anticoagulant effect of heparin infused at a constant rate. Br Med J (Clin Res Ed). 1985; 290(6465):341-4. PMC: 1417335. DOI: 10.1136/bmj.290.6465.341. View

13.

TIETZ N, Fiereck E . A specific method for serum lipase determination. Clin Chim Acta. 1966; 13(3):352-8. DOI: 10.1016/0009-8981(66)90215-4. View

14.

Mielke Jr C, Kaneshiro M, Maher I, Weiner J, RAPAPORT S . The standardized normal Ivy bleeding time and its prolongation by aspirin. Blood. 1969; 34(2):204-15. View

15.

HELLEM A . Platelet adhesiveness in von Willebrand's disease. A study with a new modification of the glass bead filter method. Scand J Haematol. 1970; 7(5):374-82. View

16.

Salzman E, Deykin D, SHAPIRO R, Rosenberg R . Management of heparin therapy: Controlled prospective trial. N Engl J Med. 1975; 292(20):1046-50. DOI: 10.1056/NEJM197505152922002. View

17.

Hirsh J, Van Aken W, Gallus A, Dollery C, Cade J, Yung W . Heparin kinetics in venous thrombosis and pulmonary embolism. Circulation. 1976; 53(4):691-5. DOI: 10.1161/01.cir.53.4.691. View

18.

Olivecrona T, Bengtsson G, Marklund S, Lindahl U, Hook M . Heparin-lipoprotein lipase interactions. Fed Proc. 1977; 36(1):60-5. View

19.

Mant M, OBrien B, Thong K, Hammond G, Birtwhistle R, GRACE M . Haemorrhagic complications of heparin therapy. Lancet. 1977; 1(8022):1133-5. DOI: 10.1016/s0140-6736(77)92388-1. View

20.

Norman C, Provan J . Control and complications of intermittent heparin therapy. Surg Gynecol Obstet. 1977; 145(3):338-42. View